StockNews.AI
SLS
StockNews.AI
91 days

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

1. Dr. Angelos Stergiou will present at A.G.P. Virtual Healthcare Showcase. 2. SELLAS focuses on novel cancer therapies, including GPS and SLS009. 3. GPS targets WT1 protein in various tumor types for cancer treatment. 4. SLS009 shows high response rate in AML patients with poor prognostic factors.

4m saved
Insight
Article

FAQ

Why Bullish?

Investor interest may rise post-fireside chat, similar to past events positively impacting stocks.

How important is it?

The company's participation in prominent healthcare events typically boosts visibility and interest, which could drive stock performance.

Why Short Term?

Immediate investor interest could be stimulated, but long-term impacts depend on trial results.

Related Companies

MDVLCRBPAMGN
May 20, 2025 08:00 ET  | Source: SELLAS Life Sciences Group, Inc. NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on Wednesday, May 21, 2025 at 8:20 am ET. A.G.P. Virtual Healthcare Company Showcase Details: Format: Fireside chat Date: Wednesday, May 21, 2025Time: 8:20 a.m. ETWebcast Link: Click Here About SELLAS Life Sciences Group, Inc.SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com. Investor Contact Bruce MackleManaging DirectorLifeSci Advisors, LLCSELLAS@lifesciadvisors.com

Related News